EsoBiotec’s ENaBL platform enables rapid, scalable cell therapy treatments, bypassing traditional complexities and making transformative therapies more accessible to patients.

EsoBiotec’s groundbreaking ESO-T01 shows promising early results in multiple myeloma, achieving cancer-free bone marrow in the first patient without requiring lymphodepletion—read more about this potential game-changer.

EsoBiotec SA has announced the launch of a clinical trial for ESO-T01, marking a significant step forward in developing innovative treatments for multiple myeloma. Early data from the study are expected in the second half of 2025.